芦可替尼治疗真性红细胞增多症长期结局的动态预后模型
研究基于PV-ARC观察性研究中178例芦可替尼治疗的真性红细胞增多症患者,在中位随访3.50年后,构建了6个月时评估的PV-RR6预后模型。模型识别3个独立风险因素:芦可替尼剂量<10mg每日两次、脾长未缩小≥50%、需放血≥2次,将患者分为低、中、高风险组,5年无事件生存率分别为89.4%、71.0%和38.9%。
要点
- PV-RR6模型在芦可替尼治疗6个月时评估,可早期识别高危患者。
- 三个独立风险因素:低剂量芦可替尼、脾未缩小≥50%、反复放血需求。
- 低、中、高风险组5年EFS分别为89.4%、71.0%、38.9%。
核心结论
- PV-RR6预后模型可早期识别芦可替尼治疗的真性红细胞增多症患者中结局不良的高危人群,支持及时优化治疗。
研究设计与样本
- 基于观察性PV-ARC研究,纳入178例羟基脲失败后接受芦可替尼治疗的真性红细胞增多症患者,中位随访3.50年。
主要发现
- 随访期间15例死亡、7例血栓、9例出血、21例进展为骨髓纤维化,5年无事件生存率为70.4%。
- PV-RR6模型将患者分为低危(评分0,5年EFS 89.4%,n=63)、中危(评分1-2.5,EFS 71.0%,n=82)和高危(评分>2.5,EFS 38.9%,n=33)。
关键数值与推荐
- 评分规则:1个时间点需放血计1分;≥2个时间点需放血或≥1个时间点芦可替尼<10mg每日两次计2分;脾长未缩小≥50%计2.5分。
- 风险分组:低危评分0,中危评分1-2.5,高危评分>2.5。
临床怎么用
- 在芦可替尼治疗6个月时应用PV-RR6模型评估风险,对中高危患者考虑优化治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ruxolitinib is widely used in polycythemia vera (PV) following hydroxyurea failure. However, validated response criteria to predict long-term outcomes in ruxolitinib-treated patients are lacking, complicating clinical decision-making. We investigated predictors of event-free survival ([EFS]; including progression to post-PV myelofibrosis, thrombosis, hemorrhages, or death) after 6 months of ruxolitinib in 178 patients with PV enrolled in the observational PV-ARC study. After a median follow-up from ruxolitinib start of 3.50 years, 15 patients died, 7 had a thrombosis, 9 had a hemorrhage, and 21 progressed to myelofibrosis. Overall, 5-year EFS was 70.4%. Leukocytosis, thrombocytosis, phlebotomy need, lack of spleen length reduction ≥50% (SR50), and ruxolitinib dose <10 mg twice daily at 3 time points (baseline and months 3 and 6), were tested for association with EFS. Multivariable analysis identified 3 independent risk factors: (1) ruxolitinib dose <10 mg twice daily at ≥1 time point (hazard ratio [HR], 1.94; P = .047), (2) no SR50 at months 3 and 6 (HR, 2.65; P = .009), (3) phlebotomy requirement at ≥2 time points (HR, 2.11; P = .039). Points were assigned as follows: 1 to phlebotomies at 1 time point; 2 to phlebotomies at ≥2 time points and to ruxolitinib <10 mg twice daily at ≥1 time point; and 2.5 to lack of SR50. Based on cumulative scores, we developed the PV-response to ruxolitinib after 6 months (PV-RR6) prognostic model, identifying 3 risk categories: low (score 0: 5-year EFS, 89.4% [n = 63]), intermediate (score 1-2.5: EFS, 71.0% [n = 82]), and high (score >2.5: EFS, 38.9% [n = 33]). PV-RR6 enables early identification of patients at risk of poor outcomes, supporting timely treatment optimization in ruxolitinib-treated patients. This trial was registered at www.clinicaltrials.gov as NCT06134102.
引用
- Palandri F, Dedola A, Caocci G, et al. A dynamic prognostic model for polycythemia vera long-term outcomes in patients treated with ruxolitinib. Blood Adv. 2026. PMID: 42275537. doi:10.1182/bloodadvances.2026020255
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。